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ABSTRACT
Poor long-term adherence and persistence to drug therapy is
universally recognized as one of the major clinical issues in the
management of chronic diseases, and patients with renal dis-
eases are also concerned by this important phenomenon.
Chronic kidney disease (CKD) patients belong to the group of
subjects with one of the highest burdens of daily pill intake
with up to >20 pills per day depending on the severity of their
disease. The purpose of the present review is to discuss the dif-
ﬁculties encountered by nephrologists in diagnosing and
managing poor adherence and persistence in CKD patients in-
cluding in patients receiving maintenance dialysis. Our review
will also attempt to provide some clues and new perspectives
on how drug adherence could actually be addressed and poss-
ibly improved. Working on drug adherence may look like a
long and tedious path, but physicians and healthcare providers
should always be aware that drug adherence is in general much
lower than what they may think and that there are many ways
to improve and support drug adherence and persistence so
that renal patients obtain the full beneﬁts of their treatments.
Keywords: chronic kidney diseases, drugs, hyperparathyroid-
ism, hypertension
INTRODUCTION
The main objectives of the management of patients with
chronic kidney diseases (CKD) are as follows: (1) to slow the
progression toward end-stage renal disease (ESRD) by control-
ling the underlying renal disease but also factors contributing to
the deterioration of renal function such as hypertension,
(2) to manage common complications of CKD such as
hyperphosphataemia, acidosis or anaemia, which may also par-
ticipate in the degradation of kidney function and (3) to identify
and manage comorbidities (diabetes, coronary heart disease,
heart failure, etc.) that lead to the increased risk of mortality
and hospitalization of CKD patients [1]. Once on dialysis, the
goals are changing slightly being mainly focused on treating
complications (anemia and hyperparathyroidism) and prevent-
ing the high morbidity and mortality associated with mainten-
ance dialysis [2].
These therapeutic goals can hardly be achieved without life-
style measures and substantial drug treatments dedicated to
each of these medical problems which add to one another
along the course of the patient’s disease starting most fre-
quently with hypertension and followed later on by anaemia,
acidosis and phosphocalcic disorders [3]. Thus, patients with
CKD and those receiving dialysis belong to the group of
chronic patients with the highest daily pill burden, comparable
with patients with HIV or severe cardiac diseases [4, 5]. Thus,
a recent survey of patients on maintenance dialysis in the USA
reported a median number of 19 pills with one-quarter of
them taking >25 medications daily [6]. In earlier stages of
CKD, patients are treated with a mean of 6–12 medications
[7]. As expected, such a high pill burden is inevitably associated
with major problems of drug adherence, the number of drugs
being an important determinant of long-term drug adherence in
chronic diseases [6]. Thus, as in many other chronic diseases, a
low adherence to drug treatments (down to 3%) as well as a low
adherence to nutritional recommendations has been reported in
CKD and dialysis patients [8].
The purpose of the present review is to discuss drug adher-
ence issues in patients with CKD Stage 1–5 in view of the most
recent literature. Although adherence is also a major concern in
renal transplantation, this topic will not be addressed and readers
are referred to some recent reviews on the topic [9, 10].
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Drug adherence is commonly deﬁned as the extent to which a
patient’s behaviour, with respect to taking medication, corre-
sponds with agreed recommendations from healthcare providers.
Adherence can be divided into two main components: persist-
ence and execution. Persistence is deﬁned as the time from
initiation to discontinuation of therapy whereas the execution
refers to the comparison between the prescribed drug dosing
regimen and the patient’s drug history while on treatment. The
latter deﬁnition includes dose omissions (missed doses) and the
so-called drug holidays (three or more days without drug intake).
The minimal percentage of adherence necessary to obtain the full
beneﬁts of a drug is generally unknown and often set arbitrarily
at 80%.
FREQUENCY OF POOR ADHERENCE IN CKD
PATIENTS : THE DIFFICULTY TO OBTAIN
RELIABLE DATA
Numerous studies have analysed the adherence rates to drug
therapies in patients with CKD or on maintenance dialysis. The
general conclusion of these studies is that poor drug adherence
is frequent among CKD patients but there is always a wide
range of ﬁgures depending on which aspect of drug therapy is
investigated. Thus, in a large survey of quantitative studies ex-
ploring predictors of non-adherence to phosphate-binding
medications in maintenance dialysis, Karamanidou et al. re-
ported a range of non-adherence to phosphate binders from 21
to 74% in 34 studies addressing speciﬁcally this issue [11]. In
two large studies evaluating hypertension management in CKD,
∼30% of patients were considered as having a poor adherence
leading to uncontrolled blood pressure (BP) [12,13].
There are several reasons for the wide variations in esti-
mations of low adherence. First, the deﬁnition of drug adher-
ence is often inconsistent. Second, the methods used to
measure drug adherence are not very reliable and tend to over-
estimate drug adherence. This is the case for example for the
Morisky questionnaire that was used in many studies includ-
ing the REGARDS study [13]. Interestingly, when different
methods are used in the same study, large variations in adher-
ence are observed. Besides being a major cause of ignoring
drug adherence in clinical practice, the lack of simple and
reliable methods to measure drug adherence also remains a
major limitation to any effective improvement in adherence-
related medication problems. As discussed recently [14], the
ideal method should provide a reliable capture, storage, analy-
sis and communication of dosing history data in ways that
make it difﬁcult or impossible for patients or trial staff to
censor or otherwise manipulate the data. Methods that meet
these criteria today include the following: retrospective analy-
sis of prescription reﬁll records [1], analysis of chemical
markers of drug exposure [2] and automatic electronic time-
stamping and compilation of events more or less strongly
linked to the act of taking medication (e.g. package opening,
dosage form dissolution) [3]. Other methods, such as
questionnaires, interviews and periodic counts of patients’ re-
turned, untaken doses, are subject to many uncertainties and
easy manipulation by patients. Today, electronic monitoring of
drug adherence is probably the most reliable method to assess the
patients’ behaviour toward drug therapy. Using this method, we
learned that drug adherence is a dynamic process and that there
is no clear and well-deﬁned cutoff below which a patient can be
considered non-adherent as this may change depending on the
type of therapy. Finally, white-coat adherence (e.g. the phenom-
enon that medication adherence tends to improve around the
time of a scheduled clinical visit but declines thereafter) is a
crucial phenomenon that affects our evaluation of adherence
[14]. Unfortunately, in CKD patients, the complexity of drug
therapies often limits the use of electronic monitors because
several treatments should be monitored simultaneously, which is
due to ﬁnancial and practical reasons often not feasible. Never-
theless, physicians and healthcare professionals should be aware
that drug adherence is probably much lower than what has been
measured in clinical studies. At last, as in other chronic diseases,
the major issue of poor adherence is related to the absence of
long-term persistence of therapy rather than occasional forgetful-
ness [14].
HYPERTENSION MANAGEMENT AND
ADHERENCE IN CKD PATIENTS
Hypertension develops early in CKD patients and is an impor-
tant determinant of the progression of CKD toward end-stage
renal diesease (ESRD). An adequate control of BP results in a
slower decline in renal function [15]. Therefore, a strict control
of blood pressure (BP) is recommended in all CKD patients with
a target BP of <130/80 mmHg and more recently <140/90
mmHg according to the last European Society of Hypertension
(ESH) guidelines [16].
As reported recently in the KEEP study (Kidney Early Evalu-
ation Program) involving 10 813 CKD patients, the BP control
rate remains low in CKD patients with 13.2% of patients having
<130/80 mmHg [17]. In a study of 7227 CKD patients followed at
a Veterans Administration Medical Centre, BP targets were
achieved only in 35% of patients [12], and in the reasons for geo-
graphic and racial differences in stroke (REGARDS) study, 36.2%
of patients had a BP of >140/90 mmHg but 61.6% had a BP of
>130/80 mmHg [13]. Drug adherence was assessed using the
medication possession ratio in the VA study [12] and using the
Morisky questionnaire in the REGARDS study [13]. Not surpris-
ingly, >30% of patients were poorly adherent, a percentage that
might well be even greater in reality. Of note, a Brazilian study,
which measured drug adherence longitudinally in CKD patients,
has shown that drug adherence (measured by self-report) tends to
improve as renal function deteriorates, suggesting that with the
progression of the kidney disease both physicians and patients
become more concerned by the quality of BP control [18].
In patients on maintenance dialysis, the BP control rate does
not appear to be better although patients adequately dialysed
tend to normalize their BP, suggesting an important role of the
duration and quality of dialysis [19]. The evaluation of BP
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measurement issues and by the absence of a clear deﬁnition of
BP targets that should be obtained in these patients [20].
However, the results of meta-analyses suggest that antihyperten-
sive therapy leads to signiﬁcant beneﬁts in dialysed patients [21].
Nonetheless, poor adherence to antihypertensive therapy is also
common in dialysis. In an Italian survey involving 1238 haemo-
dialysis patients in 54 centres, only 47% of patients were adher-
ent to their treatment [22]. Several factors are associated with
poor adherence in dialysis. The most common are as follows:
younger age, male gender, poor quality of social support, an elev-
ated number of comorbidities, health beliefs and mood
disorders—predominantly depression—a frequent complication
in patients on maintenance dialysis [23].
HYPERPHOSPHATAEMIA AND
HYPERPARATHYROIDISM MANAGEMENT
AND ADHERENCE IN CKD PATIENTS
Hyperphosphataemia and secondary hyperparathyroidism
develop relatively late in the course of renal diseases and
concern essentially patients on maintenance dialysis [3]. High
plasma phosphorus is recognized as a signiﬁcant independent
risk factor for cardiovascular morbidity and mortality by pro-
moting vascular calciﬁcations [24]. Phosphate binders and
drugs prescribed for controlling serum parathyroid hormone
(vitamin D analogues and calcimimetics) are main contribu-
tors and account for about one-half of the daily pill burden in
dialysed patients [6]. Indeed, patients are generally prescribed
1–2 tablets of phosphate binders at each meal. It is no surprise
that adherence to phosphate binders is low under these cir-
cumstances. According to the international Dialysis Outcome
and Practice Pattern Study, <50% of dialysis patients have con-
trolled phosphorus, suggesting a poor adherence to phosphate
binders as well as to dietary recommendations [25]. As stated
earlier, in a recent review of 34 published studies, drug adher-
ence to phosphate binders ranged between 22 and 74% (mean
51%), depending on the method used to assess drug adherence
[11]. This can be explained by the facts that most phosphate
binders are still of large size, difﬁcult to swallow or to chew
with a minimum of water and not particularly tasty. In fact,
the prescription of phosphate binders is an excellent example
of the negative feedback on drug adherence when increasing
the dose and number of pills in patients whose serum phos-
phorus is not on target. If serum phosphorus remains high,
physicians tend to increase the prescription of phosphate
binders without considering the possibility of a low drug ad-
herence. Consequently, the new prescription only aggravates
the situation and deteriorates drug adherence further.
Drug adherence seems to be also a concern with the admin-
istration of vitamin D or its analogues and with calcimimetics.
Indeed, the prevalence of 25-OH vitamin D deﬁciency
remains high in patients with CKD with or without dialysis
[26,27] whereas some clinical beneﬁts of vitamin D sup-
plementation have been demonstrated clinically [28]. The high
prevalence of vitamin D deﬁciency among CKD 5 patients
strongly suggests major problems of drug adherence and/or
prescribing strategies. In recent years, calcimimetics have been
developed to improve the management of secondary hyper-
parathyroidism in dialysis patients. These drugs are effective
but their use is sometimes limited by a low tolerability proﬁle
due to gastrointestinal discomfort [29]. A large survey of 4923
dialysis patients has recently demonstrated that drug adher-
ence to cinacalcet is relatively low with 46% non-adherent,
27% of low adherence and only 28% highly adherent patients
at 12 months, an observation which may have a high economic
impact [30]. In a recent controlled study, drug adherence to ci-
nacalcet could actually be improved by using an electronic
drug adherence monitoring-based approach. In brief, cinacal-
cet adherence was monitored using an electronic system for 6
months. Drug prescription was adapted according to the
results of drug adherence, and results were discussed with the
patients in motivational interviews [31]. This so-called inte-
grated care approach enabled the unmasking and improve-
ment of drug adherence problems, to transiently achieve better
PTH control, at a lower dose of cinacalcet (Figure 1). Patients
with poor adherence at baseline beneﬁted mostly, suggesting
that in this patient group the integrated care approach should
be proposed before increasing cinacalcet dose.
ADHERENCE TO OTHER CONCOMITANT
THERAPIES IN CKD PATIENTS
In addition to hypertension and mineral metabolism, CKD
patients often receive treatments to reduce their cardiovascular risk
including aspirin and statins. In addition, >25% of patients are
treated for type 2 diabetes. At last anaemia management represents
another burden in CKD Stage 5 patients but the management of
anaemia is now increasingly performed through intravenous infu-
sions of iron and subcutaneous erythropoietin injections.
In the general population, drug adherence to primary and
secondary prevention of cardiovascular diseases is rather low
and decreases with time to reach ∼50% at 1 year [32]. This is
probably also the case in CKD and dialysis patients. Thus, in a
French survey on quality of care in CKD patients [33], only
F IGURE 1 : Effect of adherence monitoring on the 6-month dose of
cinacalcet necessary to control parathyroid hormone in dialysis
patients. UC, usual care; IC, intervention (electronic monitoring of
drug adherence + counseling), from ref. [31]. *P < 0.03. Note that the
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one-third of the patients were on statins, which is rather low if
one considers the high cardiovascular risk and recent cardiol-
ogy guidelines recommending treatment in all patients with a
high risk of cardiovascular event whatever the level of choles-
terol [34]. Moreover, the use of statins was found to be effec-
tive in reducing cardiovascular events in non-dialyzed CKD
patients [35]. In maintenance dialysis, no clear beneﬁt of
statins has been observed so far in controlled studies. In the
MASTERPLAN study, in which 788 patients with CKD 2 to 5
were enrolled with a follow-up of 4.6 years, 60% of patients
were prescribed a statin, 40% received aspirin and 20%
glucose-lowering drugs [36]. A modest increase in these per-
centages was observed using multifactorial intervention with
nurse practitioners [36].
CAUSES AND POTENTIAL STRATEGIES TO
IMPROVE DRUG ADHERENCE IN CKD
PATIENTS
In order to develop rational strategies to improve drug adher-
ence in CKD patients, it appears important to identify the
reasons why these patients decide at any time not to take their
drugs, decisions that may well differ depending on their health
conditions and complexity of their treatments. This was actu-
ally explored in a recent study using structured interviews of
adult patients with CKD 3 to 5 [37]. As expected, reasons for
deciding to withhold some treatments were as follows: con-
cerns about polypharmacy (pill burden), the fear of drug
interactions, pill size and frequency, cost of drugs, and doubts
on the real efﬁcacy of some of the prescribed drugs, lack of un-
derstanding and poor communication with physicians [37]. In-
terestingly, patients tend to rank the importance of their
treatments based on the expected beneﬁts (reduction of symp-
toms) and/or side-effects. Thus, strategies to improve drug ad-
herence in CKD patients should primarily focus on the patient’s
(and physician’s) motivations as well as on developing trust and
empathy providing as much information as possible on the ne-
cessity of taking all of these drugs. In dialysis patients, Neri et al.
have actually illustrated the relationship between the adherence
probability and the number of tablets per day according to the
perception of the patient’s burden of therapy. As shown in
Figure 2, not only the number of tablets but also the perception
of the patient plays an important role in reducing the prob-
ability of an adequate adherence (Figure 2) [11].
When evaluating drug therapies themselves, the focus
should be on simplifying drug regimens for example using
ﬁxed-dose combinations enabling once daily dosing for hyper-
tension or drugs with longer duration of action to prevent the
effect of missed doses [38]. The pill burden can also be
reduced by using newer drugs administered less frequently.
This is the case for example of iron therapy, which can now be
administered safely intravenously at higher doses with newer
forms of iv iron. Another example is the monthly adminis-
tration of erythropoietin-stimulating agents available in many
countries. Regarding phosphate binders, new compounds are
being developed, which can normalize serum phosphorus
with only three pills a day [39]. In maintenance dialysis
patient, one strategy could be to administer a maximum of
drugs intravenously at the end of the dialysis session or orally
under direct supervision. In this context, new vitamin D ana-
logues such as paracalcitol have been developed, which can be
administered intravenously for the management of secondary
hyperparathyroidism [40]. With the same idea in mind, a new
form of intravenous calcimimetic is now being developed.
Among all strategies investigated to improve drug adherence
which were more or less successful [41], one interesting ap-
proach is the development of a team-based strategy involving
specialized nurses and/or pharmacists in order to enhance the
control rates of the various risk factors (hypertension, diabetes,
dyslipidaemia, etc.) [36,42–44]. Several such programmes have
been initiated in North America and Europe and demonstrated
some clear improvements in the percentage of patients ade-
quately treated and reaching therapeutic goals in CKD [42–44].
Thus, in Canada, the participation of community pharmacists
in a multidisciplinary team including nephrologists, nurses and
pharmacists enabled the improvement of the control of BP in
participants with stage 2–4 CKD [44]. In the multifactorial
approach and superior treatment efﬁcacy in renal patients with
the aid of nurse practitioners (MASTERPLAN) study con-
ducted in the Netherlands, specialized nursing care clearly im-
proved the management of cardiovascular risk factors at 1 and 2
years in patients with stage 3–4 CKD randomized to the inter-
vention arm as compared with the control group [36]. A recent
systematic review and meta-analysis of team-based randomized
studies has actually conﬁrmed the potential beneﬁts of such in-
terventions [45]. However, some doubts remain on the econ-
omical aspects of these interventions [46] and whether the
team-based approach really reduces cardiovascular end points
as well as the progression toward ESRD remains uncertain [36].
CONCLUSIONS
The goal of the present review was to re-emphasize the crucial
role of drug adherence in the management of CKD patients at
any stage of the disease including on maintenance
F IGURE 2 : Relationship between the number of tablets per day and
the probability of adherence according to the perception of the
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haemodialysis. Poor adherence should be taken into consider-
ation in all clinical situations in which targets are not reached
despite substantial efforts to prescribe the most adequate thera-
pies. Because of the complexity of treatment and the high pill
burden, CKD patients are at very high risk of poor adherence
and should deﬁnitively be supported in their efforts to maintain
a good persistence. Physicians and all other healthcare profe-
ssionals should be aware of the different strategies available to
help their patients and should join their efforts to alleviate the
barriers to good adherence by improving the communication,
reducing the pill burden and if possible by monitoring drug
adherence occasionally when there is suspicion of poor
adherence.
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